Safety Evaluation of Intracoronary infusion of extracellular vesicles in patients with AMI (EV‐AMI)

This research tests a new product for patients who have had a heart attack (AMI, acute myeocardial infarction). This product would help protect and regenerate cells in a heart damaged by AMI.

Rion is a clinical‐phase regenerative medicine company based in Rochester, MN, focused on bringing novel regenerative technologies solving unmet medical needs of the people of Minnesota.

The overarching goal of this study is to establish a first in patient experience with a first of its kind off‐the‐shelf exosome technology (PEP) in the setting of acute myocardial infarction. The primary objective of the study is to establish acute safety and feasibility for the therapy. The secondary objective is to establish chronic safety, while exploring efficacy endpoints to guide future evaluation in later phase trials.